01
Approval belongs to a product and indication.
FDA approval means the agency reviewed a specific product for one or more defined uses and determined that its benefits outweigh its known and potential risks under the labeled conditions of use.
Approval is not a universal endorsement of every use, patient, route, formulation, or product containing a similarly named ingredient.
02
Compounded drugs are not FDA-approved.
FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounding can meet legitimate patient needs when an approved product is not medically appropriate, but that purpose does not create product equivalence.
Quality, potency, sterility, storage, and impurity risks remain product and facility questions. A prescription does not turn a compounded preparation into an approved generic.
03
Non-approval does not mean inactivity.
A molecule can be biologically active and still unapproved. Retatrutide has randomized human outcomes while remaining investigational. CJC-1295 has measurable human pharmacology without established body-composition outcomes.
The correct conclusion is not “unapproved, therefore ineffective.” It is “the exact claim, product, evidence, and safety record still need to be assessed.”
04
Approval does not prove every promoted use.
Tesamorelin is approved for a narrow HIV-associated visceral-fat indication, not general weight management. Bremelanotide is approved for a defined form of HSDD in certain premenopausal women, not universal sexual performance.
Read the indications and limitations section before repeating an approval claim.
05
Use a four-question product check.
- Which exact product was approved or studied?
- Which indication, population, route, and endpoint were reviewed?
- Is the product under discussion approved, compounded, investigational, counterfeit, or research-labeled?
- What evidence supports equivalence between the two?
06 · Approval record
Approval reviews a complete application, not a molecule in the abstract
A new drug application tells the product’s full development story. FDA describes an application as including preclinical and clinical data, analyses, pharmacology, manufacturing information, proposed labeling, and safety updates. Reviewers evaluate whether evidence supports safety and effectiveness for the intended use and whether the product can be manufactured to appropriate quality standards.
The benefit-risk decision is contextual. A risk that may be acceptable for a serious disease with limited options may not be acceptable for a minor condition. Approval therefore belongs to the product, intended population, indication, route, and labeled conditions reviewed. It does not certify every off-label theory, related molecule, different formulation, or product from another source.
The approved label is the public operational boundary of that review. It identifies indications, limitations, warnings, adverse reactions, populations, and other product-specific information. An approval announcement without the label can omit the details most important for interpreting a claim.
07 · Generic distinction
A compounded drug is not an approved generic
FDA-approved generics use an abbreviated application pathway, but “abbreviated” does not mean evidence-free. FDA requires an approved generic to contain the same active ingredient and meet requirements related to strength, dosage form, route, quality, performance, and intended use. Bioequivalence or other scientific evidence supports substitution for the reference product.
Compounded drugs do not go through that premarket approval process. FDA states that it does not verify their safety, effectiveness, or quality before marketing. A compounder may prepare a medication for a legitimate patient need, such as removing an ingredient a patient cannot tolerate or creating a form an individual can use. That medical role does not turn the preparation into a generic or establish therapeutic equivalence.
The distinction matters whenever a clinic or advertisement cites an approved product’s studies. A shared active-ingredient name cannot supply the missing product review. The compounded preparation may differ in source material, concentration, excipients, delivery system, packaging, stability, and quality controls.
08 · Oversight
503A pharmacies and 503B outsourcing facilities occupy different frameworks
Federal law describes conditions under which certain compounded drugs may qualify for exemptions from parts of the standard new-drug framework. Section 503A generally concerns compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, for identified patients under specified conditions. State boards of pharmacy typically have primary day-to-day oversight of state-licensed pharmacies, while FDA also has inspection and enforcement roles.
Section 503B created outsourcing facilities. These facilities register with FDA, are subject to current good manufacturing practice requirements, and are inspected by FDA on a risk-based schedule. Registration is not product approval, and an outsourcing-facility product is not an FDA-approved drug. The framework changes oversight and production conditions; it does not create a reviewed indication or transfer efficacy evidence.
A reader should identify the actual compounder, facility status, prescription context, and applicable product rather than treating “compounded” as one uniform category. Claims such as “made by an FDA-registered facility” can be technically true while implying a level of product approval that does not exist.
09 · Availability
Shortage policy is not a permanent equivalence pathway
Federal compounding conditions can permit certain activity when a drug appears on FDA’s shortage list and other legal requirements are met. The shortage status can change. A product that was eligible to be compounded under one set of circumstances may not remain eligible after the shortage resolves or an enforcement-discretion period ends.
Shortage-related availability also does not prove that a compounded version is identical to an approved product. It addresses access under defined conditions, not a blanket scientific finding of equivalence. Readers should separate three questions: whether compounding is legally permitted in the situation, whether the product has adequate quality, and whether the claim is supported by evidence for that exact preparation.
This is especially important for highly promoted metabolic products. FDA’s current page on unapproved GLP-1 drugs warns about fraudulent labels, dosing errors, adverse-event reporting, salt forms, and products marketed directly to consumers. Retatrutide has an even clearer boundary: FDA states that it cannot be used in compounding under federal law and has not been found safe and effective for any condition.
10 · Quality evidence
A certificate of analysis answers only the questions it actually tested
A certificate may report identity, purity, potency, sterility, endotoxin, or another attribute, but readers need the method, specification, laboratory, sample source, date, and chain of custody. A test on a seller-selected sample may not represent every vial or batch. An identity result does not prove concentration; chemical purity does not prove sterility; and a result at release does not prove stability after shipping or storage.
Compounded sterile products require particular attention because poor practices can cause contamination or incorrect strength. FDA notes that quality failures have led to serious injury and death. The relevant evidence includes the facility’s controls, inspection and recall history where available, validated processes, beyond-use dating, packaging, and handling—not simply a marketing badge.
None of this means every compounded preparation is defective. It means quality is product- and facility-specific and should be demonstrated rather than inferred. The same neutral standard should apply whether a reader is enthusiastic or skeptical.
11 · Status language
Use regulatory words precisely
“Approved” means FDA has approved a marketing application for the product and use. “Investigational” means the product is being studied and lacks approval for routine marketing. “Compounded” describes preparation under a compounding framework; it does not mean approved, generic, counterfeit, or automatically unlawful. “Research use only” is a label statement and cannot establish suitability for human use.
“FDA registered” often describes a facility or listing obligation, not premarket review of the advertised product. “Made in an FDA-inspected facility” likewise does not mean FDA approved the drug or endorses every item produced there. The net impression of the claim matters more than the presence of technically correct words.
The safest public explanation pairs the status with its consequence: “This specific product is FDA-approved for this indication,” “this molecule remains investigational,” or “compounded drugs are not FDA-approved and are not premarket-reviewed for safety, effectiveness, or quality.” Precision helps readers understand evidence without turning regulatory status into a simplistic good-or-bad score.
12 · Applied decision path
Work from the exact product outward
Suppose a page says a peptide is “FDA approved.” Search Drugs@FDA for the named product and active ingredient. Confirm the application, marketing status, dosage form, route, sponsor, approval history, and current label. Then compare the advertised indication and population with the label. If the ingredient is approved only in another product or for another use, rewrite the statement narrowly.
If the item is compounded, identify the actual pharmacy or outsourcing facility rather than the prescribing platform alone. Determine whether the claim describes an individualized preparation, an approved-product copy, or an investigational substance. Check FDA shortage information and current safety communications when relevant. Legal and regulatory details can change, so a historical screenshot is not sufficient for a current conclusion.
Next separate access from evidence. A clinician’s prescription can establish a treatment decision within a professional relationship; it does not convert the preparation into an FDA-approved product or independently prove the advertised outcome. Facility registration and testing can add quality information without creating an approved indication. Each statement should be credited only with what it establishes.
Then examine product identity. Record the active substance, form, concentration, excipients, route, container, storage, beyond-use date, and compounder. Compare those details with the product used in the cited evidence. If the claim depends on equivalence, look for analytical, pharmacokinetic, bioequivalence, or clinical evidence adequate to bridge the difference. A certificate showing identity alone is not the whole bridge.
Finally write a status sentence and an evidence sentence separately. For example: “This is a compounded preparation and is not FDA-approved. The cited trial studied an approved or investigational product under different manufacturing and protocol controls, so equivalent effectiveness for this preparation has not been established.” Separating the sentences prevents regulatory status from being mistaken for a complete efficacy judgment.
This process also protects against unfair dismissal. If a compounded product addresses a legitimate patient-specific need, that context can be acknowledged while product equivalence remains uncertain. Accurate education can recognize the role of compounding without marketing it as preapproved or treating it as inherently fraudulent.
For a current audit, save the exact pages and dates used. FDA shortage decisions, safety alerts, labels, facility status, and enforcement policies can change. A conclusion that was accurate during a shortage or under temporary enforcement discretion may later become stale. Regulatory literacy includes both precision and time: identify the governing record, quote its scope fairly, and schedule a recheck when the underlying status is likely to move.
Do not turn this workflow into personal legal or medical advice. It is a public evidence check. Individual eligibility, lawful prescribing, and patient-specific risk require professionals with access to the complete facts and current jurisdictional rules.
When evidence or status cannot be confirmed, say “not confirmed” and name the missing record. Uncertainty is more useful than a confident guess.
That wording gives a future reviewer a concrete place to resume the investigation when new documentation becomes available.
It also prevents an absent record from being quietly rewritten as either proof or disproof.
Sources